1. Home
  2. APVO vs SPHL Comparison

APVO vs SPHL Comparison

Compare APVO & SPHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.28

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Logo Springview Holdings Ltd Class A Ordinary Shares

SPHL

Springview Holdings Ltd Class A Ordinary Shares

N/A

Current Price

$2.62

Market Cap

7.3M

ML Signal

N/A

Company Overview

Basic Information
Metric
APVO
SPHL
Founded
2016
2002
Country
United States
Singapore
Employees
N/A
71
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
7.3M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
APVO
SPHL
Price
$4.28
$2.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
35.6K
16.5K
Earning Date
03-26-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
0.13
N/A
EPS
N/A
N/A
Revenue
$3,114,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.35
52 Week High
$13.11
$25.11

Technical Indicators

Market Signals
Indicator
APVO
SPHL
Relative Strength Index (RSI) 34.02 42.46
Support Level $3.95 $2.46
Resistance Level $7.65 $3.35
Average True Range (ATR) 0.36 0.28
MACD -0.02 0.03
Stochastic Oscillator 20.72 20.43

Price Performance

Historical Comparison
APVO
SPHL

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

About SPHL Springview Holdings Ltd Class A Ordinary Shares

Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.

Share on Social Networks: